Patients with nonresectable, advanced or metastatic esophageal squamous cell cancer (ESCC) MedDRA version: 18.1 Level: LLT Classification code 10015363 Term: Esophageal cancer NOS System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 18.1 Level: LLT Classification code 10062478 Term: Esophageal cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 18.1 Le
Conditions
Interventions
Trade Name: Vectibix
Product Name: Panitumumab
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: panitumumab
CAS Number: 339177-26-3
Concentration unit: mg/ml milligram(s
Sponsors
AIO-Studien-gGmbH
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Signed written informed consent 2. Male or female =18 years of age 3. Histologically proven squamous cell carcinoma of the esophagus, which is not curatively resectable* and not eligible for definitive radiochemotherapy**. Patients with locally recurrent disease or clearly metastatic disease (Tx, Nx, M1, locally unresectable T4, Nx, M0 or TX, N3, M0) or macroscopically residual (post-resection) disease not eligible for definitive radiochemotherapy may be enrolled. *resectability has to be defined prior to randomization according to local standards: The tumor is considered unresectable due to: T-stage, N-stage, performance status/nutritional status, co-morbidity (pulmonary function, other), tumor location upper third of the esophagus, relation to other organs/structures), patient refusal, other reasons. **eligibility to definitive radiochemotherapy will be determined according to local standards based on the extent of disease, performance status/nutritional status, co-morbidity (pulmonary function, other), volume of neighboring organs within the radiation field, patient refusal, other reasons. 4. Measurable or non-measurable disease according to RECIST 1.1 5. ECOG 0-1 6. Women of child-bearing potential must have a negative pregnancy test 7. Laboratory requirements · Hematology: oAbsolute neutrophil count =1.5x109/L oPlatelet count =100x109/L oLeukocyte count > 3.0x109/L oHemoglobin = 9 g/dL or 5.59 mmol/l · Hepatic Function: o Total bilirubin = 1.5 time the upper normal limit (UNL) o AST = 2.5xUNL in absence of liver metastases, or =5xUNL in presence of liver metastases o ALT = 2.5xUNL in absence of liver metastases, or =5xUNL in presence of liver metastases · Renal Function: o Creatinine clearance =50 mL/min according to Cockroft-Gault formula · Metabolic Function o Magnesium = 0.5 mmol/L or 1.2 mg/dL o Calcium = 2 mmol/L or 8.0 mg/dL Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 210 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 90
Exclusion criteria
Exclusion criteria: 1. Previous chemotherapy of esophageal cancer in the metastatic setting. Previous neoadjuvant chemotherapy or definitive radiochemotherapy with a maximum cumulative dose of 120 mg cisplatin and without recurrence of disease within 4 months after the end of treatment is allowed. 2. Concurrent radiotherapy involving target lesions used for this study. Concurrent palliative radiation for non-target lesions is allowed if other lesions are available outside the involved field. Previous pre-operative or post-operative radiotherapy is allowed. 3. Previous exposure to EGFR-targeted therapy 4. Other previous malignancy with exception of a history of a previous curatively treated basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix or other curatively treated malignant disease without recurrence after at least 5 years of follow-up 5. Known brain metastases unless adequately treated (surgery or radiotherapy) with no evidence of progression and neurologically stable off anticonvulsants and steroids 6. Serious concomitant disease or medical condition that in the judgment of the investigator renders the subject at high risk of treatment complication or reduces the probability of assessing clinical effect. 7. Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) £ 1 year before enrolment 8. Inadequate pulmonary function according to the investigator’s judgment, history of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan. 9. Hearing loss > NCI-CTC V.4.03 Grade 3 10. Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment. 11. Subject (male or female) is not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment. 12. Contraindications to receive any platin, 5-FU or panitumumab 13. Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 30 days prior to treatment start 14. Current drug abuse/alcohol abuse interfering with compliance with the study requirements 15. Peripheral polyneuropathy > NCI-CTC V 4.03 Grade 2 16. Chronic inflammatory bowels diseases 17. Social situations limiting the compliance with the study requirements. 18. History of HIV infection or chronic hepatitis B or C 19. Concurrent treatment with brivudin or sorivudin or its chemically related analogues. There must be at least a 4-week wash-out period between end of treatment with brivudin, sorivudin or its chemically related analogues and start of therapy with 5-FU.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To demonstrate superiority of 5-fluorouracil, cisplatin and panitumumab over 5-fluorouracil and cisplatin alone in terms of overall survival in esophageal cancer;Secondary Objective: To compare treatment arms with respect to: • Progression-free survival • 1-year survival • Response rate • Safety and tolerability • Quality of Life ;Primary end point(s): Overall survival ;Timepoint(s) of evaluation of this end point: Date of death | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): 1 Progression-free survival 2 1-year survival 3 Response rate 4 Safety and tolerability 5 Quality of Life;Timepoint(s) of evaluation of this end point: 1 between randomisation and determination of progressive disease 2 One year after randomisation 3 between randomisation and end of treatment visit 4 between randomisation and end of treatment visit 5 randomisation, followed by every cycle until end of treatment visit | — |
Countries
Austria, Belgium, Germany, Israel, Spain
Contacts
Public ContactAIO-Studien-gGmbH
AIO-Studien-gGmbH
Outcome results
None listed